Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.42 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685383 | 0.80 | CA1 (0.52) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL11148692 | 0.80 | CA1 (0.52) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL63468 | 0.78 | ALDH1A1 (0.67) | ALDH1A1TSHRKIF11IDO1CES2 | |
| SCHEMBL29377645 | 0.78 | LTA4H (0.50) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL255255 | 0.76 | CA1 (0.58) | CA1CA2CA9MAOB | |
| SCHEMBL22015095 | 0.76 | CA1 (0.48) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL5609451 | 0.76 | CA1 (0.48) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL16578067 | 0.76 | KIF11 (0.48) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL9876731 | 0.76 | CA1 (0.48) | CA1CA2CA9ALDH1A1TSHR | |
| SCHEMBL8087112 | 0.76 | CA1 (0.54) | CA1CA2CA9ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | CA1 3596/4885CA2 355/4885CA9 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.